Clinical trials show a favorable AKI benefit with empagliflozin and dapagliflozin but not with canagliflozin.2,5,6 Similarly, empagliflozin but not canagliflozin reduce histologic markers of tubular damage and biomarkers of AKI in AKI rat models.7 The mechanisms underlying these differences may involve variabilities in SGLT2 inhibitors' off-target effects and SGLT2 selectivity.7 The gene discussed is SLC5A2; the disease is acute kidney injury.